Reply to Vivek Ramaswamy Presidential candidate

Forum Index » Political Discussion

Reply to "Vivek Ramaswamy Presidential candidate "

Subject:

Emoticons





More smilies

Text Color: Font: Close Marks

[quote=Anonymous][quote=Anonymous][quote=Anonymous][quote=Anonymous][quote=Anonymous][quote=Anonymous]Slick indeed.[twitter]https://twitter.com/nycsouthpaw/status/1694758525770047891?s=46&t=kf1qYlCXQnKgUhJWEIu2vg[/twitter][/quote]

Tech bros with no political experience have not been vetted as intensely as politicians. As his past is scrutinized, there will be suggestions of self-dealing, insider trading, fraud, etc. because that’s how fortunes are made. [/quote]

all rich people are crooks?  is that like saying all poor people are lazy?  grow up.[/quote]

DP but that’s not what she said.  And yes, getting extreme wealth often takes doing at least questionable things. Most super wealthy didn’t make their money by inventing or creating something, they did it by taking advantage of other people. [/quote]

OMG, shut up.  What a completely ridiculous claim. 
DP[/quote]

Read up on this guy. His superpower is that he is a very persuasive hedge fund guy who can convince a bunch of other hedge fund guys and venture capitalists and institutional investors to give him piles of money for his pharmaceutical firms that mostly bought patents of drugs that had failed clinical trials from the big pharma corporations and convincing the investors that his team of geniuses could fix them. Then when they failed the trials again a lot of investors lost a lot of money but his investment was structure so that he still made hundreds of millions of dollars.

Here is your sociopathic genius at work in 2018: 
https://www.biopharmadive.com/news/ramaswamy-has-no-regrets-about-axovant/517020/

[i]…Axovant Sciences focuses on neuroscience and has been a Wall Street darling, bringing in $315 million in its initial public offering. The company promised to bring a disease-modifying therapy for Alzheimer’s disease to market by developing a discarded asset from GlaxoSmithKline plc.

…While the company rode that momentum to a 52-week high near $30 per share, all came crashing down in September when Axovant announced that intepirdine failed in a late-stage trial. That failure was compounded in January when the company chose to abandon the asset altogether.

…Shares of Axovant approached the $1 per share mark when Hung abruptly exited this week.

…Despite the major rise and fall of Axovant, Ramaswamy did not seem deterred, and continues to firmly believe in the mission of his family of companies.[/i][/quote]

Options

	Disable HTML in this message
	Disable BB Code in this message
	Disable smilies in this message

Review message

Search Recent Topics Hottest Topics